Stock Scorecard

Stock Summary for Taysha Gene Therapies Inc (TSHA) - $5.69 as of 6/3/2026 11:31:49 AM EST

Total Score

8 out of 30

Safety Score

26 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for TSHA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TSHA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TSHA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TSHA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TSHA (26 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Financial Details for TSHA

Company Overview
Ticker TSHA
Company Name Taysha Gene Therapies Inc
Country N/A
Description Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date N/A

Stock Price History
Last Day Price 5.69
Price 4 Years Ago 2.26
Last Day Price Updated 6/3/2026 11:31:49 AM EST
Last Day Volume 1,550,435
Average Daily Volume 2,331,968
52-Week High 7.30
52-Week Low 2.25
Last Price to 52 Week Low 152.89%

Valuation Measures
Trailing PE N/A
Industry PE 80.56
Sector PE 58.19
5-Year Average PE -9.99
Free Cash Flow Ratio 5.93
Industry Free Cash Flow Ratio 28.83
Sector Free Cash Flow Ratio 25.14
Current Ratio Most Recent Quarter 14.04
Total Cash Per Share 0.96
Book Value Per Share Most Recent Quarter 0.87
Price to Book Ratio 8.00
Industry Price to Book Ratio 10.66
Sector Price to Book Ratio 8.28
Price to Sales Ratio Twelve Trailing Months 225.78
Industry Price to Sales Ratio Twelve Trailing Months 9.91
Sector Price to Sales Ratio Twelve Trailing Months 9.46
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 3

Share Statistics
Total Shares Outstanding 287,361,000
Market Capitalization 1,635,084,090
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -22.06%
Reported EPS 12 Trailing Months -0.38
Reported EPS Past Year -0.11
Reported EPS Prior Year -0.31
Net Income Twelve Trailing Months -129,875,999
Net Income Past Year -108,995,000
Net Income Prior Year -89,298,000
Quarterly Revenue Growth YOY 171.30%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -1,774.00%

Balance Sheet
Total Cash Most Recent Quarter 276,576,000
Total Cash Past Year 319,767,000
Total Cash Prior Year 139,036,000
Net Cash Position Most Recent Quarter 227,615,000
Net Cash Position Past Year 269,661,000
Long Term Debt Past Year 50,106,000
Long Term Debt Prior Year 43,942,000
Total Debt Most Recent Quarter 48,961,000
Equity to Debt Ratio Past Year 0.83
Equity to Debt Ratio Most Recent Quarter 0.81
Total Stockholder Equity Past Year 246,938,000
Total Stockholder Equity Prior Year 71,525,000
Total Stockholder Equity Most Recent Quarter 211,944,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -112,332,000
Free Cash Flow Per Share Twelve Trailing Months -0.39
Free Cash Flow Past Year -93,828,000
Free Cash Flow Prior Year -81,599,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.02
MACD Signal 0.25
20-Day Bollinger Lower Band 3.39
20-Day Bollinger Middle Band 5.05
20-Day Bollinger Upper Band 6.71
Beta 1.23
RSI 39.71
50-Day SMA 4.22
150-Day SMA 2.83
200-Day SMA 0.00

System
Modified 6/2/2026 9:46:43 AM EST